Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2015

Open Access 01-12-2015 | Study protocol

COgnitive behavioural therapy vs standardised medical care for adults with Dissociative non-Epileptic Seizures (CODES): a multicentre randomised controlled trial protocol

Authors: Laura H. Goldstein, John D. C. Mellers, Sabine Landau, Jon Stone, Alan Carson, Nick Medford, Markus Reuber, Mark Richardson, Paul McCrone, Joanna Murray, Trudie Chalder

Published in: BMC Neurology | Issue 1/2015

Login to get access

Abstract

Background

The evidence base for the effectiveness of psychological interventions for patients with dissociative non-epileptic seizures (DS) is currently extremely limited, although data from two small pilot randomised controlled trials (RCTs), including from our group, suggest that Cognitive Behavioural Therapy (CBT) may be effective in reducing DS occurrence and may improve aspects of psychological status and psychosocial functioning.

Methods/Design

The study is a multicentre, pragmatic parallel group RCT to evaluate the clinical and cost-effectiveness of specifically-tailored CBT plus standardised medical care (SMC) vs SMC alone in reducing DS frequency and improving psychological and health-related outcomes. In the initial screening phase, patients with DS will receive their diagnosis from a neurologist/epilepsy specialist. If patients are eligible and interested following the provision of study information and a booklet about DS, they will consent to provide demographic information and fortnightly data about their seizures, and agree to see a psychiatrist three months later. We aim to recruit ~500 patients to this screening stage. After a review three months later by a psychiatrist, those patients who have continued to have DS in the previous eight weeks and who meet further eligibility criteria will be told about the trial comparing CBT + SMC vs SMC alone. If they are interested in participating, they will be given a further booklet on DS and study information. A research worker will see them to obtain their informed consent to take part in the RCT. We aim to randomise 298 people (149 to each arm). In addition to a baseline assessment, data will be collected at 6 and 12 months post randomisation. Our primary outcome is monthly seizure frequency in the preceding month. Secondary outcomes include seizure severity, measures of seizure freedom and reduction, psychological distress and psychosocial functioning, quality of life, health service use, cost effectiveness and adverse events. We will include a nested qualitative study to evaluate participants’ views of the intervention and factors that acted as facilitators and barriers to participation.

Discussion

This study will be the first adequately powered evaluation of CBT for this patient group and offers the potential to provide an evidence base for treating this patient group.

Trial registration

Current Controlled Trials ISRCTN05681227
ClinicalTrials.gov NCT02325544
Literature
1.
Malmgren K, Reuber M, Appleton R. Differential diagnosis of epilepsy. In: Shorvon S, editor. Oxford textbook of epilepsy and epileptic seizures. Oxford: Oxford University Press; 2012. p. 81–4.
2.
Angus-Leppan H. Diagnosing epilepsy in neurology clinics: a prospective study. Seizure. 2008;17(5):431–6.CrossRefPubMed
3.
Duncan R, Razvi S, Mulhern S. Newly presenting psychogenic nonepileptic seizures: incidence, population characteristics, and early outcome from a prospective audit of a first seizure clinic. EpilepsyBehav. 2011;20(2):308–11.
4.
Reuber M, Fernandez G, Bauer J, Helmstaedter C, Elger CE. Diagnostic delay in psychogenic nonepileptic seizures. Neurology. 2002;58:493–5.CrossRefPubMed
5.
Reuber M, Pukrop R, Bauer J, Helmstaedter C, Tessendorf N, Elger CE. Outcome in psychogenic nonepileptic seizures: 1 to 10-year follow-up in 164 patients. Ann Neurol. 2003;53(3):305–11.CrossRefPubMed
6.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th Edition-DSM-IV). Washington DC American Psychiatric Association; 1994.
7.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders Fifth edition. United States: American Psychiatric Association; 2013.
8.
World Health Organisation. The ICD-10 classification of mental and behavioural disorders. Diagnostic criteria for research. Geneva, Switzerland: World Health Organisation; 1993.
9.
Mellers JDC. The approach to patients with ‘non-epileptic seizures’. Postgrad Med J. 2005;81(958):498–504.
10.
McKenzie PS, Oto M, Graham CD, Duncan R. Do patients whose psychogenic non-epileptic seizures resolve, ‘replace’ them with other medically unexplained symptoms? Medically unexplained symptoms arising after a diagnosis of psychogenic non-epileptic seizures. J Neurol Neurosurg Psychiatry. 2011;82(9):967–9.CrossRefPubMed
11.
Duncan R, Oto M, Wainman-Lefley J. Mortality in a cohort of patients with psychogenic non-epileptic seizures. J Neurol Neurosurg Psychiatry. 2012;83(7):761–2.
12.
Al Marzooqi SM, Baker GA, Reilly J, Salmon P. The perceived health status of people with psychologically derived non-epileptic attack disorder and epilepsy: a comparative study. Seizure. 2004;13:71–5.CrossRefPubMed
13.
Goldstein LH, Mellers JD. Ictal symptoms of anxiety, avoidance behaviour, and dissociation in patients with dissociative seizures. J Neurol Neurosurg Psychiatry. 2006;77(5):616–21.CrossRefPubMedPubMedCentral
14.
Dimaro LV, Dawson DL, Roberts NA, Brown I, Moghaddam NG, Reuber M. Anxiety and avoidance in psychogenic nonepileptic seizures: The role of implicit and explicit anxiety. Epilepsy Behav. 2014;33:77–86.CrossRefPubMed
15.
Martin RC, Gilliam FG, Kilgore M, Faught E, Kuzniecky R. Improved health care resource utilization following video-EEG-confirmed diagnosis of nonepileptic psychogenic seizures. Seizure. 1998;7(5):385–90.CrossRefPubMed
16.
Magee JA, Burke T, Delanty N, Pender N, Fortune GM. The economic cost of nonepileptic attack disorder in Ireland. Epilepsy Behav. 2014;33:45–8.CrossRefPubMed
17.
Razvi S, Mulhern S, Duncan R. Newly diagnosed psychogenic nonepileptic seizures: health care demand prior to and following diagnosis at a first seizure clinic. Epilepsy Behav. 2012;23(1):7–9.CrossRefPubMed
18.
Ahmedani BK, Osborne J, Nerenz DR, Haque S, Pietrantoni L, Mahone D, et al. Diagnosis, costs, and utilization for psychogenic non-epileptic seizures in a US health care setting. Psychosomatics. 2013;54(1):28–34.
19.
Mayor R, Smith PE, Reuber M. Management of patients with nonepileptic attack disorder in the United Kingdom: a survey of health care professionals. Epilepsy Behav. 2011;21(4):402–6.CrossRefPubMed
20.
Goldstein LH, Mellers JDC. Recent developments in our understanding of the semiology and treatment of psychogenic nonepileptic seizures. Curr Neurol Neurosci Rep. 2012;12(4):436–44.CrossRefPubMed
21.
Reuber M, Mayor R. Recent progress in the understanding and treatment of nonepileptic seizures. Curr Opin Psychiatry. 2012;25(3):244–50.CrossRefPubMed
22.
LaFrance Jr WC, Reuber M, Goldstein LH. Management of psychogenic nonepileptic seizures. Epilepsia. 2013;54 Suppl 1:53–67.CrossRefPubMed
23.
Martlew J, Pulman J, Marson AG. Psychological and behavioural treatments for adults with non-epileptic attack disorder. The Cochrane database of systematic reviews. 2014;2, CD006370.PubMed
24.
Goldstein LH, Chalder T, Chigwedere C, Khondoker MR, Moriarty J, Toone BK, et al. Cognitive-behavioral therapy for psychogenic nonepileptic seizures A pilot RCT. Neurology. 2010;74(24):1986–94.
25.
LaFrance Jr WC, Baird GL, Barry JJ, Blum AS, Webb AF, Keitner GI, et al. Multicenter pilot treatment trial for psychogenic nonepileptic seizures: a randomized clinical trial. JAMA Psychiatry. 2014;71(9):997–1005.
26.
Agrawal N, Fleminger S, Ring H, Deb S. Neuropsychiatry in the UK: national survey of existing service provision. Psychiatric Bull. 2008;32(8):288–91.CrossRef
27.
Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008;337(7676):a1655.CrossRefPubMedPubMedCentral
28.
Guy W. ECDEU assessment manual for psychopharmacology. Rockville, MD: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
29.
Hall-Patch L, Brown R, House A, Howlett S, Kemp S, Lawton G, et al. Acceptability and effectiveness of a strategy for the communication of the diagnosis of psychogenic nonepileptic seizures. Epilepsia. 2010;51(1):70–8.
30.
Rusch MD, Morris GL, Allen L, Lathrop LA. Psychological treatment of nonepileptic events. Epilepsy Behav. 2001;2:277–83.CrossRefPubMed
31.
LaFrance Jr WC, Miller IW, Ryan CE, Blum AS, Solomon DA, Kelley JE, et al. Cognitive behavioral therapy for psychogenic nonepileptic seizures. Epilepsy Behav. 2009;14(4):591–6.
32.
Chalder T. Non-epileptic attacks: a cognitive behavioural approach in a single case approach with a four-year follow-up. Clin Psychol Psychother. 1996;3(4):291–7.CrossRef
33.
Goldstein LH, Deale AC, Mitchell-O’Malley SJ, Toone BK, Mellers JD. An evaluation of cognitive behavioral therapy as a treatment for dissociative seizures: a pilot study. Cogn Behav Neurol. 2004;17(1):41–9.CrossRefPubMed
34.
Goldstein LH, LaFrance Jr WC, Chigwedere C, Mellers JDC, Chalder T. Cognitive behavioral treatments. In: Schachter SC, LaFrance Jr WC, editors. Gates and Rowan’s Non-epileptic Seizures. 3rd ed. Cambridge: Cambridge University Press; 2010. p. 281–8.
35.
Lang PJ. Fear reduction and fear behaviour: problems in treating a construct. In: Shilen JM, editor. Research in Psychotherapy (Vol III). Washington DC: American Psychological Association; 1968.
36.
Cella M, Stahl D, Reme SE, Chalder T. Therapist effects in routine psychotherapy practice: an account from chronic fatigue syndrome. Psychotherapy Res. 2011;21(2):168–78.CrossRef
37.
Kuyk J, Siffels MC, Bakvis P, Swinkels WAM. Psychological treatment of patients with psychogenic non-epileptic seizures: an outcome study. Seizure. 2008;17(7):595–603.CrossRefPubMed
38.
Mayor R, Howlett S, Gruenewald R, Reuber M. Long-term outcome of brief augmented psychodynamic interpersonal therapy for psychogenic nonepileptic seizures: seizure control and health care utilization. Epilepsia. 2010;51(7):1169–76.CrossRefPubMed
39.
Germans S, Van Heck GL, Hodiamont PPG. Results of the search for personality disorder screening tools: clinical implications. J Clin Psychiatry. 2012;73(2):165–73.CrossRefPubMed
40.
Germans S, Van Heck GL, Moran P, Hodiamont PPG. The Self-report Standardized Assessment of Personality-Abbreviated Scale: preliminary results of a brief screening test for personality disorders. Pers Mental Health. 2008;2(2):70–6.
41.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22–33.
42.
Rimes KA, Chalder T. The Beliefs About Emotions Scale: validity, reliability and sensitivity to change. J Psychosom Res. 2010;68(3):285–92.
43.
Baldwin SA, Murray DM, Shadish WR, Pals SL, Holland JM, Abramowitz JS, et al. Intraclass correlation associated with therapists: estimates and applications in planning psychotherapy research. Cogn Behav Ther. 2011;40(1):15–33.
44.
Borm GF, Fransen J, Lemmens WA. A simple sample size formula for analysis of covariance in randomized clinical trials. J Clin Epidemiol. 2007;60(12):1234–8.CrossRefPubMed
45.
White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ. 2011;342:d40.CrossRefPubMedPubMedCentral
46.
Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, editor. Measuring Mental Health Needs. London: Gaskell; 2001.
47.
Curtis L. Unit Costs of Health and Social Care 2011. 2011.
48.
Department of Health. NHS reference costs. London: Department of Health; 2012.
49.
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5 L). Qual Life Res. 2011;20(10):1727–36.
50.
Ware J Jnr, Kosinksi M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–33.
51.
Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004;42(9):851–9.CrossRefPubMed
52.
Furber C. Framework analysis: a method for analysing qualitative data. Afr J Midwifery Women’s Health. 2010;4(2):97–100.
53.
Cramer JA, Baker GA, Jacoby A. Development of a new seizure severity questionnaire: initial reliability and validity testing. Epilepsy Res. 2002;48(3):187–97.CrossRefPubMed
54.
Mundt JC, Marks IM, Shear MK, Greist JH. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002;180:461–4.
55.
Spitzer RL, Kroenke K, Williams JBW, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Int Med. 2006;166:1092–7.CrossRef
56.
Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Int Med. 2001;16(9):606–13.CrossRef
57.
Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002;64:258–66.CrossRefPubMed
58.
Sharpe MSJ, Hibberd C, Warlow C, Duncan R, Coleman R, Roberts R, et al. Neurology out-patients with symptoms unexplained by disease: illness beliefs and financial benefits predict 1-year outcome. Psychol Med. 2010;40(4):689–98.
59.
Connell JC, Barkham M. CORE-10 user manual, version 1.1. CORE System Trust & CORE Information Management System Ltd; 2007.
Metadata
Title
COgnitive behavioural therapy vs standardised medical care for adults with Dissociative non-Epileptic Seizures (CODES): a multicentre randomised controlled trial protocol
Authors
Laura H. Goldstein
John D. C. Mellers
Sabine Landau
Jon Stone
Alan Carson
Nick Medford
Markus Reuber
Mark Richardson
Paul McCrone
Joanna Murray
Trudie Chalder
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2015
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-015-0350-0

Other articles of this Issue 1/2015

BMC Neurology 1/2015 Go to the issue

Research article

May clinical neurophysiology help to predict the recovery of neurological early rehabilitation patients?

Research article

Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial

Study protocol

Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson’s disease: the LEAP-study

Research article

Asystole in the epilepsy unit

Study protocol

A prospective web-based patient-centred interactive study of long-term disabilities, disabilities perception and health-related quality of life in patients with multiple sclerosis in The Netherlands: the Dutch Multiple Sclerosis Study protocol

Research article

Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease